Protalix Forward Looking Statement Disclaimer

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties related to the timing of a commercial launch in Brazil and other countries; decisions by regulatory authorities in various countries regarding whether and when to approve drug applications that have been or may be filed for taliglucerase alfa in such countries as well as their decisions regarding labeling and other matters that could affect its availability or commercial potential; the risk that applicable regulatory authorities may refuse to approve the marketing and sale of a drug product even after acceptance of an application filed for the drug product; and risks related to competitive developments. The statements in this release are valid only as of the date hereof, and Protalix disclaims any obligation to update this information. These and other risks and uncertainties are detailed under the heading "Risk Factors" in Protalix's Annual Report on Form 10-K for the year ended December 31, 2012.

PFIZER DISCLOSURE NOTICE: The information contained in this release is as of March 18, 2013. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking statements about taliglucerase alfa (generic name: alfataliglicerase in Brazil, trade name: UPLYSO in Brazil) that involve substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties regarding the commercial success of UPLYSO in Brazil; decisions by regulatory authorities in various other countries regarding whether and when to approve drug applications that have been or may be filed for taliglucerase alfa in such countries as well as their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2012 and in its reports on Form 10-Q and Form 8-K.
CONTACT: Pfizer Contacts:                  Sharon Castillo (Media)         202-494-6769         Sharon.J.Castillo@pfizer.com                  Suzanne Harnett (Investors)         212-733-8009         Suzanne.Harnett@pfizer.com                  Protalix Contacts:                  Kari Watson (Media)         MacDougall Biomedical         Communications         781-235-3060         kwatson@macbiocom.com                  Marcy Beth Nanus (Investors)         The Trout Group, LLC         646-378-2927         MNanus@troutgroup.com

If you liked this article you might like

Protalix Cystic Fibrosis Drug Study Results Worsen Over Time

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

5 Stocks Under $10 Set to Soar

5 Stocks Insiders Love Right Now

5 Stocks Ready to Break Out and Soar Higher